Detalhe da pesquisa
1.
Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.
Respir Res
; 25(1): 107, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38419035
2.
Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies.
Int Immunopharmacol
; 99: 107985, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34435584
3.
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
Cancer Chemother Pharmacol
; 79(2): 339-351, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28058445
4.
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
Cancer Chemother Pharmacol
; 78(6): 1185-1197, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27796539